Zastumotide

Drug Profile

Zastumotide

Alternative Names: Astuprotimut-R; D1/3 MAGE-3 fusion protein; D1/3 MAGE-3 fusion protein SB MAGE-3; D1/3 MAGE-3 His; D1/3 MAGE-3 His fusion protein; GSK 1572932A; GSK 2132231A; GSK 249553; GSK1203486A; MAGE-A3; MAGE-A3 antigen specific cancer immunotherapeutic; MAGE-A3 ASCI; NSC 719274; SB 249553; SB MAGE-3; SID 534984

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Ludwig Institute for Cancer Research
  • Class Cancer vaccines; Immunotherapies; Peptides; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; MAGEA-3-protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Malignant melanoma
  • No development reported Multiple myeloma
  • Discontinued Bladder cancer; Non-small cell lung cancer

Most Recent Events

  • 05 Jan 2017 No development reported - Phase-I for Multiple myeloma in USA (IM)
  • 15 Dec 2016 Biomarkers information updated
  • 15 Apr 2016 Interim adverse events and efficacy data from a phase II trial in Malignant melanoma (Inoperable/Unresectable, Combination therapy) presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top